12 Panel Drug Test: Substances, Detection Times, and Rights

A 12-panel drug test screens a single urine specimen for twelve categories of controlled substances, and it is one of the broadest standard panels used in workplace, legal, and clinical settings. Most 12-panel screens cover amphetamines, cocaine, opiates, oxycodone, marijuana (THC), PCP, benzodiazepines, barbiturates, methadone, buprenorphine, tramadol, and an alcohol biomarker, though the exact list depends on the laboratory and the entity ordering the test.¹ It goes well beyond the five-panel test the Department of Transportation requires for safety-sensitive workers, and it is used by employers, probation officers, and family courts to get a fuller picture than a basic screen provides.² Because panels are not standardized across all providers, knowing exactly which substances yours covers, how long each stays detectable, and what rights you have if something is flagged can prevent expensive surprises.

What’s Actually on the Panel

There is no single universal 12-panel test. Providers build their panels around a common core and swap in one or two categories depending on the customer and the setting. A widely used configuration from a major national laboratory covers these twelve substance classes:¹

Amphetamines, including methamphetamine, MDMA, and prescription stimulants like Adderall.
Cocaine, detected through its metabolite benzoylecgonine.
Opiates, covering codeine, morphine, and heroin (detected as 6-acetylmorphine).
Oxycodone, tested separately because standard opiate immunoassays often miss it.
Marijuana (THC), which looks for the metabolite produced after the body processes THC.
Phencyclidine (PCP).
Benzodiazepines like alprazolam, diazepam, and lorazepam.
Barbiturates.
Methadone, used for pain management and addiction treatment.
Buprenorphine, commonly prescribed in opioid recovery programs.
Tramadol, a pain reliever with opioid-like properties.
Alcohol biomarkers (EtG/EtS), which detect recent alcohol use through metabolites that persist longer than alcohol itself.

Fentanyl is the most important recent addition to drug testing. As of July 7, 2025, the Department of Health and Human Services added fentanyl and its metabolite norfentanyl to the federal workplace drug testing panel for both urine and oral fluid specimens.³ The initial urine screening cutoff is set at just 1 ng/mL because fentanyl is potent in extremely small quantities. Standard opiate immunoassays do not reliably detect it, so a separate assay is required. Many private employers now include fentanyl on their 12-panel screens, but if your test was ordered before the 2025 update or uses an older panel configuration, it may not be covered at all.

Ask the provider or your employer for the specific panel composition before you test. The substance you are worried about may or may not be on the list.

How Long Each Substance Stays Detectable

Detection windows depend on the drug’s chemistry, your metabolism, and how often you have used it. These ranges reflect typical urine detection times for a single or occasional use:

Cocaine: one to two days.
Amphetamines and methamphetamine: one to four days, extending to a week with heavy use.
MDMA: one to three days.
Opiates (codeine, morphine, heroin): one to three days.
Oxycodone: one to three days.
Methadone: one to fourteen days, substantially longer than most opioids.
Benzodiazepines: highly variable, from one day for short-acting forms to weeks for long-acting ones like diazepam.
Barbiturates: short-acting types clear in a few days; long-acting phenobarbital can persist for weeks.
PCP: one to seven days for occasional use, potentially longer with heavy use.
Fentanyl: roughly one to three days after short-term use; chronic use can extend detection to several weeks as the drug accumulates in fatty tissue.
Marijuana (THC): the major outlier, detectable from a few days in occasional users to 30 days or more in chronic users because THC metabolites accumulate in fat cells.

Marijuana catches people off guard more than anything else on this list. A one-time user might clear the 50 ng/mL federal screening threshold within a few days, but someone who uses daily could still test positive well over a month after stopping.³ Body weight, hydration, liver function, and exercise all affect how quickly your body eliminates metabolites. A result only counts as positive when it exceeds the specific cutoff for that substance.

What Happens During Collection

Bring a valid government-issued photo ID like a driver’s license or passport.⁴ Employer-directed tests usually come with a Chain of Custody Form or authorization document from the employer or its third-party administrator, and the collection site may not proceed without that paperwork. Also bring a list of your current prescription medications and the prescribing physicians, because that information helps the Medical Review Officer resolve any flagged results.

Collection follows a standardized protocol built to prevent tampering. You will remove outer clothing, empty your pockets, and leave bags and phones in a secured area. The restroom typically has blue dye in the toilet water and shut-off faucets to prevent dilution. You provide a mid-stream sample into a sterile container and hand it to the collector. The specimen’s temperature is checked within four minutes and must fall between 90 and 100 degrees Fahrenheit.⁵ A reading outside that range triggers an immediate recollection under direct observation. The collector also checks for unusual color, foaming, chemical odor, or foreign objects.

You and the collector sign the Chain of Custody Form, and the specimen is sealed with tamper-evident tape in your presence. That form tracks the sample through every step of laboratory analysis. A break in the chain can invalidate results, which is why collectors follow the steps rigidly.

If You Can’t Provide Enough Urine

Federal protocol gives you up to three hours and up to 40 ounces of fluid to try again.⁶ You are not required to drink the fluid, but you must stay at the site. If you still cannot provide a sufficient sample after three hours, the collection ends and your employer is notified. The employer then directs you to a medical evaluation to determine whether a physiological reason explains the inability to produce a sample. If the evaluating physician finds no adequate medical explanation, the result is recorded as a refusal.

How Results Are Analyzed and Reviewed

The laboratory first runs an initial immunoassay screen. It is fast and cost-effective but considered presumptive, because cross-reactivity with other substances can produce false positives. Any sample screening positive at or above the established cutoff is sent to confirmatory testing using mass spectrometry, which identifies the exact molecular structure of the substance present. Modern labs increasingly use liquid chromatography-tandem mass spectrometry, which requires less sample preparation and can identify a broader range of compounds in a single run.

Federal cutoffs vary significantly by substance. Marijuana metabolites screen at 50 ng/mL and confirm at 15 ng/mL. Amphetamines screen at 500 ng/mL. Fentanyl screens at just 1 ng/mL.³ Private employer panels may use different cutoffs, but these federal thresholds set the baseline most laboratories follow.

Before results reach the employer or court, a Medical Review Officer reviews every confirmed positive. The MRO is a licensed physician whose job at this stage is determining whether a legitimate medical explanation accounts for the result.⁷ The MRO contacts you directly and asks about prescriptions, medical treatments, or other lawful reasons for the substance in your system. If you hold a valid prescription for oxycodone and the confirmed substance is oxycodone, the MRO will typically report the result as negative. This step is the most important safeguard for anyone taking legally prescribed medications that happen to appear on the panel.

Prescriptions, CBD, and False Positives

Over-the-counter medications can trigger initial presumptive positives on the immunoassay screen. Cold and allergy medications containing pseudoephedrine or phenylephrine sometimes cross-react with the amphetamines assay. Dextromethorphan, the cough suppressant in many cold remedies, can trigger a false positive for PCP. Ibuprofen and diphenhydramine (the active ingredient in Benadryl and many sleep aids) have also been documented to cause cross-reactivity in initial screens. Confirmatory mass spectrometry testing is designed to separate these from actual controlled substances, but disclosing everything you have taken recently helps the MRO resolve flagged results faster. Bring your prescription bottles or an up-to-date medication list to the appointment.

Hemp-derived CBD products are a genuine trap. The Department of Transportation has warned that CBD product labels frequently understate their THC content, and no federal agency certifies the accuracy of those labels.⁸ If a CBD product contains enough THC to trigger a positive result, saying you only used CBD will not save you. Medical Review Officers do not accept CBD use as a legitimate explanation for a positive marijuana result.

Dilute Specimens and Retesting

A specimen is classified as dilute when its creatinine concentration falls below 20 mg/dL and its specific gravity is below 1.0030. Drinking a lot of water before the appointment, vigorous exercise, or certain medical conditions can all produce a dilute sample, so a dilute result does not automatically mean someone tried to cheat.

How the result is handled depends on whether the dilute specimen tested positive or negative. A positive dilute is treated the same as a standard positive, and the employer cannot order a retest just because the sample was dilute. A negative dilute with a creatinine level between 2 and 5 mg/dL triggers a mandatory recollection under direct observation. When creatinine is above 5 mg/dL, the employer may choose to require a retest but is not required to. If the second sample also comes back negative dilute, that result stands. Declining a directed retest counts as a refusal, which carries the same consequences as a positive.⁹ Avoid chugging water in the hours before your test, but do not dehydrate yourself either.

What Counts as a Refusal to Test

A refusal carries the same consequences as a verified positive in virtually every workplace and legal testing context. Under federal DOT regulations, all of the following are treated as a refusal:¹⁰

Leaving the collection site before the process is complete.
Failing to provide a specimen for any required test.
Providing insufficient volume when a follow-up medical evaluation finds no adequate medical explanation.
Refusing direct observation or monitored collection when required.
Possessing a prosthetic device or other tool that could interfere with collection.
Refusing to cooperate with any part of the process, including refusing to empty pockets, wash hands, or permit oral cavity inspection.
Admitting to the collector or MRO that you adulterated or substituted the specimen.
Declining a directed retest or additional test ordered by the employer.

The confrontational-behavior provision catches people off guard. Arguing with the collector, creating a disruption, or refusing a routine instruction like removing items from your mouth all qualify. In pre-employment situations, leaving before the process starts is not a refusal, but once collection has begun, walking out is treated identically to a positive.

Challenging a Positive Result

When the MRO informs you of a verified positive, you have 72 hours to request testing of the split specimen. Every specimen collected under federal protocol is divided into a primary bottle (Bottle A) and a split bottle (Bottle B) at the time of collection. If you request it, Bottle B is sent to a different HHS-certified laboratory for independent confirmation.¹¹ The MRO must be reachable during the entire 72-hour window, including outside normal business hours, so an answering machine or voicemail with a time-stamp feature must be available.

Your employer must ensure the split specimen test happens once you make a timely request. You cannot be required to pay out of pocket before the test takes place, though your employer may seek reimbursement later depending on company policy or a collective bargaining agreement.¹²

Beyond the split specimen, the most effective challenges target chain-of-custody failures and procedural violations. If the collector skipped temperature verification, failed to properly seal the specimen, or allowed an unaccounted gap in the chain of custody documentation, those errors can undermine the reliability of the result. Laboratory accreditation status and whether the facility followed SAMHSA-certified protocols are also common points of challenge. Additional tests on the specimen, such as DNA analysis, are not authorized under federal regulations.

Your Rights With Prescriptions, Recovery, and Marijuana

The MRO review process is your first line of defense if you take a legally prescribed medication that appears on the panel. Protections extend further. The Americans with Disabilities Act covers employees who use opioids or other controlled substances legally, including people enrolled in Medication Assisted Treatment programs for opioid addiction. An employer cannot fire you or refuse to hire you solely because you are in a MAT program, unless you genuinely cannot perform the job safely or another federal law disqualifies you.¹³

Employers who believe your medication interferes with safety need objective evidence of an actual impairment or significant risk. Speculation or blanket assumptions about what a medication does are not enough. If an employer wants to take action based on lawful medication use, they may be required to offer a reasonable accommodation first, such as modified scheduling, temporary reassignment, or adjusted break times. Opioid use disorder itself can qualify as a disability under the ADA, entitling you to accommodations for treatment.¹³ These protections do not apply to illegal drug use. An employee currently using a controlled substance without a prescription has no ADA protection for that use, and employers are never required to tolerate impairment on the job or ignore safety-sensitive requirements.

State marijuana laws have added another layer. As of 2025, a growing minority of legalization states have enacted employment protections for off-duty cannabis use. These laws generally prohibit employers from taking adverse action against employees for legal marijuana use outside of work, and some specifically bar employers from using tests that detect non-psychoactive THC metabolites, which can linger long after any impairment has passed. State protections typically do not apply to safety-sensitive positions, federal employees, or anyone subject to DOT-regulated testing. Federal law still classifies marijuana as a Schedule I controlled substance, and no state law can override federal testing requirements.¹⁴ If your employer tests under DOT authority, a positive THC result will be treated as a verified positive regardless of what your state allows. For non-regulated private employers, check whether your state has an off-duty use protection statute before assuming the worst about a THC-positive result on a 12-panel screen.

1
Labcorp. Drug Screen 12 With Reflex Confirmation
2
U.S. Department of Transportation. DOT 5 Panel Notice
3
Federal Register. Mandatory Guidelines for Federal Workplace Drug Testing Programs – Authorized Testing Panels
4
U.S. Department of Transportation. Urine Specimen Collection Guidelines
5
eCFR. 49 CFR 40.65 – What Does the Collector Check for When the Employee Presents a Specimen
6
U.S. Department of Transportation. 49 CFR Part 40 Section 40.193 – What Happens When an Employee Does Not Provide a Sufficient Amount of Specimen for a Drug Test
7
U.S. Department of Transportation. Medical Review Officer (MRO)
8
U.S. Department of Transportation. DOT CBD Notice
9
eCFR. 49 CFR 40.197 – What Happens When an Employer Receives a Report of a Dilute Urine Specimen
10
eCFR. 49 CFR 40.191 – What Is a Refusal to Take a DOT Drug Test, and What Are the Consequences
11
eCFR. 49 CFR 40.153 – How Does the MRO Notify Employees of Their Right to a Test of the Split Specimen
12
eCFR. 49 CFR 40.173 – Who Is Responsible for Paying for the Test of a Split Specimen
13
U.S. Equal Employment Opportunity Commission. Use of Codeine, Oxycodone, and Other Opioids – Information for Employees
14
Office of the Law Revision Counsel. 21 USC 812 – Schedules of Controlled Substances